Business Wire

FINARO

22.3.2022 17:40:03 CET | Business Wire | Pressemeddelelse

Del
Finaro udpeger Ruben Frimand Nielsen som Vicepræsident for Salg- & Forretningsudvikling for de Nordiske lande, som endnu et tiltag for at understøtte de ambitiøse vækstplaner

Finaro , den globale indløser og bank, der er specialister indenfor international handel, har i dag offentliggjort Ruben Frimand Nielsen som Vicepræsident for Salg- og Forretningsudvikling for de Nordiske lande.

Tidligere business manager hos Mastercard, Ruben, vil lede vækststrategien i Danmark, Sverige, Norge, Finland, Færøerne, Island og Grønland, side om side med udvidelsen af det globale Finaro-team. Inden han sluttede sig til Finaro, var Ruben ansvarlig for international porteføljeadministration, salg og produktstrategi, for afdelingen payments international hos Mastercard. Derfor er han klar til at bringe Finaros globale betalingsløsninger ud til virksomheder i en af de hurtigst voksende e-handels regioner i Europa.

Danske, svenske, norske og finske forbrugere brugte tilsammen 46,5 milliarder euro online i 2020, med 19% af de nordiske handlende der foretog online indkøb på tværs af grænserne . I Danmark købte mere end 90% af forbrugerne ind online i 2020, efterfulgt af 87% i Norge og 86% i Sverige . Disse tal forventes at stige i 2022, da forbrugerne har vænnet sig til disse indkøbsmetoder og gør brug af mobil handel såsom lokale digitale wallets og in-app payments.

Achiya Fried, Chief Commercial & Strategy Officer hos Finaro , fortæller: “Jeg er begejstret for, at byde Ruben velkommen. Vi har ambitiøse vækstplaner, og en central del af dette omfatter udvidelser i de Nordiske lande. Rubens betalingserfaring og viden indenfor strategi vil helt sikkert blive en af drivkrafterne for Finaros voksende fremdrift i regionen, og jeg ser frem til, at se hvad han kan gøre for teamet og for virksomheden.”

Igal Rotam, CEO for Finaro , siger: “Vi er begejstrede for, at Ruben slutter sig til vores virksomhed for at støtte denne vækst og udføre den strategiske plan for de Nordiske lande. Hans kompetencer og dybdegående indblik vil sikre, at Finaros kunder på det Nordiske marked har adgang til de innovative og banebrydende betalingsløsninger, som de har behov for, for at kunne betjene deres egne voksende globale kunder.”

Ruben Frimand Nielsen, Vicepræsident for Salg - & Forretningsudvikling hos Finaro, kommenterede om sin nye titel og arbejde : “Det er en utrolig spændende tid at blive en del af Finaro på og være en del af den stærke vækst og ambitiøse planer for fremtiden. Den varme velkomst, og mit eksisterende kendskab til virksomheden samt produkterne har givet mig en smidig overgang - og jeg ser frem til, at påtage mig rollen for væksten samt at sætte et fodaftryk på det Nordiske marked. Jeg ser frem til at komme i gang.’’

Rubens udnævnelse kommer efter det nylige skift af Finaros navn fra Credorax, der afspejler dens nye identitet og forpligtelse til at realisere dens vision for betalinger, hvor handel er uden landegrænser og fri for teknologiske, fysiske og geografiske begrænsninger. Efter et utroligt succesfuldt år i 2021, med mere end 10 milliarder US dollars i samlet behandlet volume for mere end 5.000 handelsdrivende, er Finaro dedikeret til at gøre komplekse betalinger enkle, kombineret med dens instinktive passion for kundeservice, som går langt videre end det normale.

Om Finaro

Finaro er en global betalingsudbyder der på tværs af landegrænser styrker den internationale handel gennem enkle betalinger og innovativ teknologi. Vores dedikerede team, enestående teknologiske formåen, produktinnovation og kundefokuserede tilgang, gør os i stand til at forenkle kompleksitet og skabe samlet købsoplevelse der medfører vækst og giver ro i sindet for vores kunder. For at lære mere kan du besøge www.finaro.com .

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye